Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Shentel Completes Fiber-to-the-Home Upgrade in Buchanan, Virginia
-
Economic Uncertainty Kept GTA Homebuyers on the Sidelines in September
-
PathMaker Neurosystems Announces Publication of First-Ever Study Showing Non-Invasive Clearance of Toxic TDP-43 Protein Aggregates in Preclinical ALS Study
-
Elong Power Holding Limited Announces First Half 2026 Financial Results
-
Roadzen to Present at Maxim Growth Summit and ThinkEquity Conference
-
NUCLIDIUM Announces First Patient Imaged in Phase 2 Study Evaluating 61Cu-NU101 Diagnostic in Patients with Metastatic Prostate Cancer
-
Landsbankinn hf.: Offering of covered bonds
-
Transaction in Own Shares
-
Form 8.3 - [POLLEN STREET GROUP LIMITED - 05 10 2026] - (CGAML)
-
Form 8.3 - [ADVANCED MEDICAL SOLUTIONS GROUP PLC - 05 10 2026] - (CGWL)
-
Form 8.3 - STHREE PLC
-
Form 8.3 - Gamma Communications plc
-
RESULT OF RIKSBANK CERTIFICATE SALE
-
Neinor seals new €110mn JV, brings cash forward and improves guidance to 2028
-
VirTra Wins Five-Year CBP Contract With Up to $14 Million in Potential Value
-
Transactions in connection with share buy-back program
-
Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
-
IESE launches Global CFO program
-
Notice of Additional Buyback Offer for Admiral Markets AS Bonds
-
Disclosure of total number of voting rights and number of shares in the capital at September 30, 2026
-
WUBEN Prime Day 2026 Offers Exclusive Rewards
-
Resolution Therapeutics to present interim Phase I/II EMERALD study data on RTX001 as a late-breaker at AASLD 2026
-
Optimum Strategic Communications to Host 18th Annual Healthcare Investor Conference
-
Caseware Verity-Powered Risk Suggestion Agent Launches to Help Auditors Identify Engagement-Specific Risks
-
PropLaunch Joins Forces with Axcera and RUBIK to Help Founders Launch Prop Firms
-
CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES
-
Xometry Names Marc Teulières as General Manager for Europe to Accelerate Regional Adoption
-
HI-VIEW RESOURCES COMPLETES 2026 EXPLORATION FIELD PROGRAM IN THE TOODOGGONE MINING DISTRICT, BRITISH COLUMBIA
-
Canada’s project boom could generate $443B in revenues for SMEs: BDC study
-
RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
-
Rewind Therapeutics Secures Additional Financing to Advance Oral GPR17 Remyelination Program
-
Jeppesen ForeFlight Airflow™ Agents Debut for Commercial Aviation, Centered on Operating Intelligence and Adoption Flexibility
-
Angelini Ventures and EIB Co-lead $58 Million Series A Financing in Rouge Therapeutics to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
-
RQ Bio Appoints Gavin Koh as Chief Medical Officer and Strengthens Leadership to Advance RQB01
-
One04 Therapeutics to present late-breaking interim Phase 1 results for CPV-104 in C3 glomerulopathy at ASN Kidney Week followed by Virtual KOL Event
-
One04 Therapeutics to present late-breaking interim Phase 1 results for CPV-104 in C3 glomerulopathy at ASN Kidney Week followed by Virtual KOL Event
-
Gabriel Holding A/S upwardly adjusts its expectations for the financial year 2025/26 for the continuing operations.
-
Verdora Excellence Alliance Expands Intelligent Capital and Risk Management Framework
-
New Beauty Platform GlowEra Launches to Help Women Look Their Best Without Expensive Procedures
-
LUBIS EDA Launches FormalOS: Infrastructure for Systematic, Scalable Formal Verification
-
KVB Accelerates Middle East Footprint with Strategic MENA Regional Expansion
-
LG U+ selects the Digital Vending Machine® from Bango to expand its subscription bundling
-
Equinor ASA: Share buy-back – third tranche for 2026
-
Statement regarding possible offer
-
Production update and FTSE 250 Index inclusion
-
NBPE Announces Transaction in Own Shares
-
Transaction in Own Shares
-
Progress on share buyback programme
-
Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market
-
Bulk Peptides: Kylo Peptides Launches Bulk Research Program for High-Volume Laboratories
